Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 701–800 of 1,150
TD-GC-MS Analysis of Volatile Metabolites of Human Lung Cancer and Normal Cells In vitro
Filipiak, W., Sponring, A., Filipiak, A., Ager, C., Schubert, J., Miekisch, W., Amann, A., & Troppmair, J. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0162 · Cited by 223
“They have been isolated originally from a lung carcinoma of a 58-y-old man and showed epithelial morphology and grew adherent (33-36).”
BackgroundKing, A. J., Arnone, M. R., Bleam, M. R., Moss, K. G., Yang, J., Fedorowicz, K. E., Smitheman, K. N., Erhardt, J. A., Hughes-Earle, A., Kane-Carson, L. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067583 · Cited by 221
“Such activating mutations appear to mimic regulatory phosphorylation of BRAF and increase its kinase activity compared with the wild-type protein [6].”
BackgroundLiang, J. Q., Teoh, N., Xu, L., Pok, S., Li, X., Chu, E. S. H., Chiu, J., Dong, L., Arfianti, E., Haigh, W. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06931-6 · Cited by 222
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., & Xu, X. (2005) · Cancer · doi:10.1002/cncr.21073 · Cited by 223
“Analysis of RAS Mutations In vitro studies have demonstrated that the transformation potential of BRAF mutant is about 50-fold lower than that of RAS.(22) Clinical studies suggest that BRAF mutation alone is not sufficient to transform melanocytes because BRAF is mutated in approximately 70% of nevi.”
BackgroundKim, T. Y., Kim, W. B., Song, J. Y., Rhee, Y. S., Gong, G., Cho, Y. M., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02389.x · Cited by 221
Shi, H., Kong, X., Ribas, A., & Lo, R. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0140 · Cited by 222
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., Atkins, M. B., Leming, P., & Kirkwood, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1529 · Cited by 221
“Approximately 50% of melanomas harbor BRAF mutations and another 20% harbor activating NRAS mutations.(25,26) Preclinical data have shown that sorafenib can inhibit the MAP kinase pathway and inhibit the proliferation of cells with either BRAF or NRAS mutations in vitro.”
BackgroundHong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Zuidervaart, W., van Nieuwpoort, F., Stark, M., Dijkman, R., Packer, L., Borgstein, A.-M., Pavey, S., van der Velden, P., Out, C., Jager, M. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602598 · Cited by 221
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 217
“A number of BRAF mutants other than V600 were identified in human cancers [28].”
Parwani, A. V. (2007) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(08)70389-x · Cited by 221
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 223
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Salem, M. E., Weinberg, B. A., Xiu, J., El-Deiry, W. S., Hwang, J. J., Gatalica, Z., Philip, P. A., Shields, A. F., Lenz, H.-J., & Marshall, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21169 · Cited by 216
“These values contrast significantly with the previously reported 5-10% BRAF mutation rate [28, 29], probably due to the fact that colon (both sides) and rectal tumors were grouped together in previous studies.”
ResultHigh-throughput kinase profiling as a platform for drug discovery
Goldstein, D. M., Gray, N. S., & Zarrinkar, P. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2541 · Cited by 215
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
“%) were Exon 15 mutations at the V600E position (Davies et al., 2002).”
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 218
“…clustering comes from examples of activating mutations in oncogenes that show strong positional preferences (such as the V600E mutation in BRAF [80] and mutations in residues 12, 13, and 61 of KRAS [81]) or inactivating mutations such as those observed in the DNA-binding domain of TP53 [82].”
BackgroundFahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Liu, W.-J., Du, Y., Wen, R., Yang, M., & Xu, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 216
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
“After the first reports of BRAF mutations in colorectal malignancy (Davies et al., 2002; Rajagopalan et al., 2002), it has soon been recognized that BRAF alterations are strongly associated with right-sided sessile cancers and its serrated precursor lesions HPs and serrated adenomas (Chan et al.,…”
BackgroundInfluentialAgaimy, A., Terracciano, L. M., Dirnhofer, S., Tornillo, L., Foerster, A., Hartmann, A., & Bihl, M. P. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.064550 · Cited by 218
“Most BRAF mutations cluster in a hot-spot at nucleotide 1799 in exon 15 leading to substitution of valine by glutamic acid at codon 600 (V600E).(7) It has been demonstrated that BRAF and KIT mutations represent mutually exclusive alternative oncogenic events in malignant melanoma.”
BackgroundRecent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
THOMPSON, N., & LYONS, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.007 · Cited by 214
Therapy for metastatic melanoma: the past, present, and future
Finn, L., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 218
“In summary, both highly selective BRAF inhibitors, vemurafenib and GSK2118436, have demonstrated excellent clinical activity with a high response rate and low toxicity in patients with BRAF V600E mutations but, unfortunately, both therapies are limited by a relatively short duration that averages around six months.”
BackgroundInfluentialRoads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
Paluncic, J., Kovacevic, Z., Jansson, P. J., Kalinowski, D., Merlot, A. M., Huang, M. L.-H., Lok, H. C., Sahni, S., Lane, D. J. R., & Richardson, D. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.025 · Cited by 219
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., Griffin, N., Bijwaard, K., Lee, E. Y., Philip, R., Jiang, X., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0642 · Cited by 218
“In NSCLC, BRAF V600E is predominantly found in tumors with adenocarcinoma histology [3].”
BackgroundYang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
“Furthermore, KRAS and BRAF mutations seem to be mutually exclusive in colorectal tumors, highlighting the importance of BRAF mutations in tumorigenesis for a subset of patients (5, 14).”
Anthrax lethal and edema toxins in anthrax pathogenesis
Liu, S., Moayeri, M., & Leppla, S. H. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.02.012 · Cited by 217
Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics
Lagerstedt Robinson, K., Liu, T., Vandrovcova, J., Halvarsson, B., Clendenning, M., Frebourg, T., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Peltomaki, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk051 · Cited by 216
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Lacouture, M. E., Duvic, M., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0333 · Cited by 218
“acid, is the most prevalent [1] and results in constitutive ERK”
BackgroundRational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Grothey, A., Fakih, M., & Tabernero, J. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 220
Haber, D. A., Gray, N. S., & Baselga, J. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 214
“Important successes of genome-scale sequencing included the discovery of highly recurrent and specific mutations in BRAF and PI3K (Davies et al., 2002; Samuels et al., 2004).”
BackgroundInfluentialCampbell, P. M., Groehler, A. L., Lee, K. M., Ouellette, M. M., Khazak, V., & Der, C. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3752 · Cited by 215
“pancreatic cancers (6), and surprisingly, up-regulated ERK”
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 216
Nagasaka, T., Sasamoto, H., Notohara, K., Cullings, H. M., Takeda, M., Kimura, K., Kambara, T., MacPhee, D. G., Young, J., Leggett, B. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.154 · Cited by 217
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.010 · Cited by 212
“MAPK pathway members are also frequently dysregulated in cancers withBRAFmutations observed in approximately 50% of malignant melanomas and subsets of lung (10%), thyroid (62%), and colorectal (20%) cancers (Cerami et al., 2012; Davies et al., 2002; Gao et al., 2013).”
BackgroundSelf-citationPIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 216
Gardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
Recent Advances on Electrochemical Biosensing Strategies toward Universal Point‐of‐Care Systems
Dai, Y., & Liu, C. C. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901879 · Cited by 216
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript of melanomas harbor mutations in BRAF, with most of the remainder containing mutations in N-RAS (Brose et al., 2002; Davies et al., 2002; Pollock and Meltzer, 2002).”
Zhang, L. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080062 · Cited by 213
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., BUSAM, K. J., & Polsky, D. (2003) · PubMed · Cited by 212
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
“The observation that BRAF is frequently mutated in several human cancers (namely melanoma, colorectal cancer, thyroid cancer, and low-grade serous ovarian cancer) led to the development of BRAF-specific inhibitors, and one such inhibitor, vemurafenib, is approved for use in late-stage melanoma with BRAF V600E mutation…”
BackgroundInfluentialMáximo, V, Botelho, T., Capela, J., Soares, P., Lima, J., Taveira, A., Amaro, T., Barbosa, A. P., Preto, A., Harach, H. R., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602547 · Cited by 214
“Screening of B-RAF mutations To screen for B-RAF mutations, we analysed DNA extracted from paraffin-embedded tumour tissue and adjacent thyroid tissue of patients who presented GRIM-19 mutations following the procedures previously described (Davies et al, 2002; Soares et al, 2003).”
MethodHuang, D., Ding, Y., Luo, W.-M., Bender, S., Qian, C.-N., Kort, E., Zhang, Z.-F., VandenBeldt, K., Duesbery, N. S., Resau, J. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5311 · Cited by 212
Finberg, K. E., Sequist, L. V., Joshi, V. A., Muzikansky, A., Miller, J. M., Han, M., Beheshti, J., Chirieac, L. R., Mark, E. J., & Iafrate, A. J. (2007) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060182 · Cited by 214
Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.004 · Cited by 215
“…M anuscript A uthor M anuscript A uthor M anuscript addition, B-Raf mutations within the kinase domain, particularly the V600E mutation, are observed in several human cancers, particularly melanoma, and are active targets for therapeutic intervention (Davies et al., 2002; Turski et al., 2016).”
BackgroundBauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00837.x · Cited by 211
“Activating mutations of the BRAF gene have been reported in the majority of melanocytic nevi and cutaneous melanoma (Davies et al., 2002; Maldonado et al., 2003; Pollock et al., 2003; Yazdi et al., 2003),”
BackgroundArozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C., Hayward, R., Viros, A., Sahai, E., & Marais, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.029 · Cited by 212
Self-citationLittle, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., & Cook, S. J. (2011) · Science Signaling · doi:10.1126/scisignal.2001752 · Cited by 210
Clarke, C. N., & Kopetz, S. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 207
“Furthermore, BRAF status is believed to be responsible for the 12-15% of pat ients who fa i l ant i -EGFR (10,13,14).”
BackgroundInfluentialColorectal Cancer Biomarkers: Where Are We Now?
Gonzalez-Pons, M., & Cruz-Correa, M. (2015) · BioMed Research International · doi:10.1155/2015/149014 · Cited by 209
“[38, 39] and are present in 40–50% of sporadic MSI-high”
BackgroundMolecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 209
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212
“melanomas (3, 4), 82% of 77 nevi of diverse histopathologies”
BackgroundResultInfluentialSun, W., Powell, M., O'Dwyer, P. J., Catalano, P., Ansari, R. H., & Benson, A. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7988 · Cited by 214
Human melanocyte senescence and melanoma susceptibility genes
Bennett, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206446 · Cited by 212
“…inhibit apoptosis via AKT activation; overexpression of a number of protein tyrosine kinases or RAS activation (both of which would also activate AKT), b-catenin activation (reviews Easty and Bennett, 2000; Halachmi and Gilchrest, 2001) and the newly reported BRAF mutations (Davies et al., 2002).”
BackgroundDeath receptors and melanoma resistance to apoptosis
Ivanov, V. N., Bhoumik, A., & Ronai, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206456 · Cited by 211
“Whereas about 20% of melanomas appear to carry mutation in the N-ras oncogene (Herlyn and Satyamoorthy, 1996; Castellano and Parmiani, 1999), over 60% were recently reported to contain mutation within the B-Raf gene (Davies et al., 2002).”
BackgroundPhase II trial of imatinib mesylate in patients with metastatic melanoma
Kim, K. B., Eton, O., Davis, D. W., Frazier, M. L., McConkey, D. J., Diwan, A. H., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Ross, M. I., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604482 · Cited by 213
“Davies et al (2002) recently showed that approximately 66% of melanomas contain somatic missense mutations, located within the kinase domain of B-Raf, with the ability to transform NIH3T3 cells.”
Cohen, Y., Rosenbaum, E., Clark, D. P., Zeiger, M. A., Umbricht, C. B., Tufano, R. P., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0273 · Cited by 207
Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K., Kefford, R., Hauschild, A., Hwu, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0321 · Cited by 206
“The discovery of a high prevalence of activating mutations in the BRAF gene in melanoma lead to the development of inhibitors designed to target BRAF mutations or MEK signaling downstream of activated B-RAF, for treatment of this disease (13-16).”
BackgroundAtg7 Overcomes Senescence and Promotes Growth of Braf V600E-Driven Melanoma
Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1473 · Cited by 208
Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz, F., Rubin, B. P., Wilson, D. J., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M. C., & Corless, C. L. (2003) · PubMed · Cited by 208
Prognostic utility of BRAF mutation in papillary thyroid cancer
Xing, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.012 · Cited by 210
“By aberrantly and constitutively activating the Ras → Raf → MAP kinase/ERK pathway (MAP kinase pathway), the resultant mutant BRAF V600E kinase is potently oncogenic (Davies et al., 2002).”
BackgroundEffects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells
Baldari, S., Di Rocco, G., Heffern, M. C., Su, T. A., Chang, C. J., & Toietta, G. (2019) · Cancers · doi:10.3390/cancers11050659 · Cited by 210
“We evaluated the impact of copper chelation on in vitro proliferation of two human colorectal carcinoma cell lines characterized by the presence of BRAFwt (HCT-116) or carrying the BRAFV600E mutation (HT-29) [3].”
BackgroundManaging Metastatic Melanoma in 2022: A Clinical Review
Switzer, B., Puzanov, I., Skitzki, J. J., Hamad, L., & Ernstoff, M. S. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00686 · Cited by 190
Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Trametinib: First Global Approval
Wright, C. J. M., & McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0096-1 · Cited by 206
“protein kinase BRAF, a constituent in the RAS-RAF-MEKERK signal-transduction pathway that mediates cellular responses to extracellular stimuli, are present in approximately 50 % of patients with advanced melanoma [2, 3].”
BackgroundAntibody-based proteomics: fast-tracking molecular diagnostics in oncology
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., & Gallagher, W. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2902 · Cited by 208
“Another example of the importance of identification of the correct patient subgroup is the use of Raf inhibitors in melanomas that harbour a BRAF mutation, which is present in approximately 50% of case”
BackgroundGoodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R. A., Larue, L., & Goding, C. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1053 · Cited by 208
“The results (Fig. 3B) showed that Brn-2 bound the probe and that binding was competed with wild-type (WT) oligonucleotide ( 1 ) corresponding to the probe sequence, but not by a mutated element 1.m that competed as poorly as an unrelated competitor containing a consensus Lef1 binding site.”
BackgroundInfluentialThe Role of Autophagy in Cancer
Santana-Codina, N., Mancias, J. D., & Kimmelman, A. C. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041816-122338 · Cited by 201
“BRAF mutations have been described in lung adenocarcinoma, melanoma, ovarian cancer, and colorectal cancer (Davies et al. 2002).”
BackgroundMargonis, G. A., Buettner, S., Andreatos, N., Kim, Y., Wagner, D., Sasaki, K., Beer, A., Schwarz, C., Løes, I. M., Smolle, M., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.0996 · Cited by 208
Zebrafish Models of Cancer—New Insights on Modeling Human Cancer in a Non-Mammalian Vertebrate
Hason, M., & Bartůněk, P. (2019) · Genes · doi:10.3390/genes10110935 · Cited by 206
“BRAF and RAS mutations seem to be mutually exclusive in cancer, however, there are rare cases when these players of the same signaling pathway coincide, which might be interesting for further studies [63,64].”
BackgroundChapter 1 Ras Signaling and Therapies
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02001-6 · Cited by 205
ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially
Vantaggiato, C., Formentini, I., Bondanza, A., Bonini, C., Naldini, L., & Brambilla, R. (2006) · Journal of Biology · doi:10.1186/jbiol38 · Cited by 207
“This figure underrepresents the actual involvement of Ras pathways in tumorigenesis, however, as other downstream signaling components, such as B-Raf, are frequently found in their oncogenic form in tumors in which Ras is not itself mutated [10].”
BackgroundInvolvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis
Eckert, L. B., Repasky, G. A., Ülkü, A. S., McFall, A., Zhou, H., Sartor, C. I., & Der, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0396 · Cited by 207
The Transcription Network Regulating Melanocyte Development and Melanoma
Vance, K. W., & Goding, C. R. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00164.x · Cited by 209
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205
Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q.-B., Gallardo, H., Liu, C., Merghoub, T., Hefter, B., et al. (2012) · Oncogene · doi:10.1038/onc.2011.250 · Cited by 207
“Mitogen-activated protein (MAP) kinase pathway activation is among the most frequent findings in human cancer and is often the result of activating mutations in BRAF (Davies et al., 2002).”
BackgroundMutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
“each exon harbors almost all of the mutations in both genes (6, 7, 11, 18).”
BackgroundNotch1 is an effector of Akt and hypoxia in melanoma development
Bedogni, B., Warneke, J. A., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36157 · Cited by 207
“Only cells expressing active Akt showed increased levels of Notch1-NIC, while in BRaf-expressing melanocytes, Notch1-NIC levels did not change compared with control cells (Figure 2D).”
BackgroundInfluentialBoussemart, L., Routier, E., Mateus, C., Opletalova, K., Sebille, G., Kamsu-Kom, N., Thomas, M., Vagner, S., Favre, M., Tomasic, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt015 · Cited by 207
Endometrial carcinoma: pathology and genetics
Prat, J., Gallardo, A., Cuatrecasas, M., & Catasús, L. (2007) · Pathology · doi:10.1080/00313020601136153 · Cited by 206
“B-RAF gene mutations have been reported in a wide range of human tumours and occur in approximately 7% of cancers.(138) The incidence is highest in malignant melanomas (27–70%) and thyroid carcinomas (36–53%), followed by colorectal carcinomas (5–22%), and ovarian serous borderline tumours and lowgrade serous carcinom…”
BackgroundSakai, T. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1015 · Cited by 206
Crucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development
Bai, Y., Edamatsu, H., Maeda, S., Saito, H., Suzuki, N., Satoh, T., & Kataoka, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3143 · Cited by 206
“Their products, Ras small GTPases, control cell proliferation and differentiation through interaction with multiple effector proteins, among which Raf kinases have been implicated in carcinogenesis from studies on in vitro transformation of fibroblast cell lines (2) and on genomic mutations in malignant melanoma (3).”
BackgroundHaber, D. A., & Settleman, J. (2007) · Nature · doi:10.1038/446145a · Cited by 203
Emuss, V., Garnett, M., Mason, C., The Cancer Genome Project, & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1683 · Cited by 207
“Genomic sequencing was done as described (9) using the primers shown in Supplementary Table 1.”
BackgroundMethodInfluentialSelf-citationPIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Janku, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Luthra, R., Garrido-Laguna, I., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022769 · Cited by 204
“BRAF mutations have been mainly reported in melanoma, colorectal, papillary thyroid, and ovarian cancer.[44,45] In colorectal cancer they are associated with a dismal prognosis, however, unlike KRAS mutations, BRAF mutations might not be predictive of lack of cetuximab benefit.”
BackgroundLovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D., Hicks, D. J., Hucks, D., Berry, E., Terry, C., Duke, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035309 · Cited by 206
“Meenhard Herlyn (The Wistar Institute): WM1963 [30], WM3682 [30], WM115 [31], WM266-4 [2], and WM3211 [32].”
InfluentialBRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
“Davies et al. (2002) found BRAF mutations in 59% of melanoma cell cultures, 80% short-term cultures and 66% of uncultured melanomas.”
BackgroundMethodResultInfluentialCoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210
“the somatic mutation of gene, a mutation in a particular amino acid residue (such as the V600E mutations in the BRAF gene that are common in colorectal and other cancers [56]), or an epigenetic change such as hypermethylation of a promoter.”
BackgroundThomas, N. E., Edmiston, S. N., Alexander, A., Groben, P. A., Parrish, E., Kricker, A., Armstrong, B. K., Anton-Culver, H., Gruber, S. B., From, L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0493 · Cited by 196
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
Abe, H., Kikuchi, S., Hayakawa, K., Iida, T., Nagahashi, N., Maeda, K., Sakamoto, J., Matsumoto, N., Miura, T., Matsumura, K., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200004g · Cited by 196
Melanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P. A., & Adams, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524808 · Cited by 204
“BRAFV599E has been shown to act as a transforming oncogene both in NIH3T3 cells (66) and in an immortalized murine melanocyte cell line (105).”
BackgroundKaroulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G., Herlyn, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.024 · Cited by 205
“The most common BRAF mutation (BRAFV600E), found in about 8% of human tumors and more than 50% of melanomas, results in ERK signaling upregulation, independent of RAS activity (Davies et al., 2002; Wan et al., 2004).”
Nong, J., Gong, Y., Guan, Y., Yi, X., Yi, Y., Chang, L., Yang, L., Lv, J., Guo, Z., Jia, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05327-w · Cited by 202
Self-citationCD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2
Antony, P. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155049.26787.45 · Cited by 205
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Chia, P. L., John, T., Dobrovic, A., & Mitchell, P. (2014) · Clinical Epidemiology · doi:10.2147/clep.s69718 · Cited by 199
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.